



ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



ORIGINAL ARTICLE

Unraveling the Link Between Bullous Pemphigoid and Neurological Disease: A Single-center Study of 257 Patients

L.M. Nieto-Benito^{a,*}, R. Suárez-Fernández^b

^a Department of Dermatology, Clínica Universidad de Navarra, Madrid, Spain

^b Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Received 3 August 2024; accepted 9 October 2024

KEYWORDS

Anti-BP180;
Anti-BP230;
Autoantibodies;
Bullous pemphigoid;
Eosinophils;
Neurological disease

Abstract

Background: Multiple studies have corroborated the association between bullous pemphigoid (BP) and neurological diseases; patients with both diseases (BP-N) have been associated with a worse prognosis and specific clinical and immunological characteristics, defining a different subtype of BP.

Objectives: We aimed to determine the prevalence and characteristics of BP cases with neurological comorbidities (BP-N) and review the related published literature.

Methods: We conducted a retrospective, observational study of BP cases treated at a referral center for autoimmune blistering diseases from January 2000 through June 2020.

Results: We collected epidemiological, clinical, histopathological, progression and laboratory data from a total of 257 cases, 102 of which were BP-N. Senile dementia, Alzheimer's disease and vascular dementia were the most frequent neurological comorbidities. Compared with cases without neurological comorbidities, BP-N cases had more intense tissue eosinophilia ($p=0.012$) and higher concentrations of circulating eosinophils ($p=0.000$), and anti-BP180 IgG antibodies ($p=0.007$). At the time of data collection, 78 BP-N were deceased.

Conclusions: Our case series highlighted the relevance of neurological comorbidities in BP patients; although the pathogenesis is still to be elucidated, the neuroinflammation present in neurodegenerative diseases could explain the neurocutaneous link and the chronological relationship between these entities.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: lula.m.nieto@gmail.com (L.M. Nieto-Benito).

<https://doi.org/10.1016/j.ad.2024.10.071>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Anti-BP180;
Anti-BP230;
Autoanticuerpos;
Enfermedad
neurológica;
Eosinófilos;
Penfigoide ampollosa

Penfigoide ampollosa y comorbilidad neurológica: ¿causa o consecuencia? Estudio retrospectivo unicéntrico de 257 pacientes

Resumen

Introducción: Múltiples estudios han corroborado la asociación entre penfigoide ampollosa (PA) y enfermedad neurológica; en ellos, se ha planteado que los pacientes con PA asociado a enfermedad neurológica tendrían unas características clínicas e inmunológicas específicas, condicionando un subtipo especial de PA, que contaría con un peor pronóstico.

Objetivos: Determinar la prevalencia y características de los casos de PA asociados a comorbilidades neurológicas (PA-N) y revisar la literatura publicada al respecto hasta la fecha.

Métodos: Estudio retrospectivo observacional de los casos de PA atendidos entre enero del 2000 y junio del 2020 en una consulta monográfica de enfermedades ampollosas autoinmunes.

Resultados: Se determinaron las características epidemiológicas, clínicas, histopatológicas, inmunológicas y evolutivas de 257 pacientes, de los cuales 102 presentaban comorbilidad neurológica. La demencia senil, enfermedad de Alzheimer y la demencia vascular fueron las más frecuentes. En comparación con pacientes con PA sin enfermedad neurológica, los casos con esta comorbilidad presentaron mayores concentraciones de eosinófilos en sangre ($p=0,000$) y de anticuerpos anti-BP180 IgG ($p=0,007$) además de una mayor eosinofilia tisular ($p=0,012$). En el momento de la recogida de datos, 78 pacientes con PA-N se encontraban fallecidos.

Conclusiones: Este estudio refleja la relevancia de las enfermedades neurológicas en pacientes con PA. Aunque la fisiopatogenia de esta asociación no ha sido bien establecida, la neuroinflamación presente en las enfermedades neurológicas, especialmente degenerativas, podría explicar la conexión neurocutánea y la relación cronológica entre ambas enfermedades.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Bullous pemphigoid (BP) is the most common autoimmune blistering disease of the skin and mucous membranes.^{1–3} Although defined as a rare condition, the incidence rate of BP has been increasing throughout time, attributed to factors such as population aging, neurological and neoplastic comorbidities, drug-induced cases and the increasing awareness of non-bullous and atypical variants of BP.^{1–4}

BP predominantly affects patients older than 65 years and the risk of developing it increases with age.^{2,3} In a typical patient, BP has been classically associated with neurological conditions,^{5,6} which are closely associated with advanced age^{3,5} and have shown an increasing prevalence in the general population.⁷ Moreover, drug-related BP cases have contributed to the rising incidence rate.^{8,9} Psychotropic and central nervous system drugs have been identified as potential inducers of dermatological conditions, including BP.^{4,8,9}

Several studies have characterized cases of BP with neurological comorbidities (BP-N)^{10–16} showing specific clinical and serological characteristics,¹¹ worse prognosis¹² and higher mortality rates.¹³ However, most of the studies were conducted in small samples and focused on epidemiological aspects, often failing to include a control group (BP patients without neurological diseases).^{12–14}

Therefore, the objectives of this study were to determine the prevalence BP-N, including all BP patients treated at a tertiary referral center for autoimmune blistering diseases, and evaluate the clinicopathological and immunological features, management, progression and prognosis of BP-N cases vs cases of BP without neurological comorbidities.

Methods

We conducted a retrospective, observational study to analyze the relationship between BP and neurodegeneration in patients treated from January 2000 through June 2020.

The diagnosis of BP was based on the criteria proposed by the European Dermatology Forum in collaboration with the European Academy of Dermatology and Venereology, as updated in their clinical practice guidelines on the management of BP.¹⁷ Only confirmed cases meeting, at least, 3 out of the 4 criteria (clinical, histopathological, serological [including indirect immunofluorescence (IIF) and/or enzyme-linked immunosorbent assay (ELISA)] and direct immunofluorescence (DIF)) were included. Patients with other dermatological conditions different from BP were excluded.

Data were collected from the databases of the dermatology and dermatopathology departments including age at onset; sex; date and comorbidities at BP diagnosis; drug use within 6 months prior to diagnosis of BP; clinical characteristics, including body surface area (BSA) affected, location, presence of pruritus, symmetry and scalp and mucous membranes involvement; absolute eosinophil count at diagnosis; serum antibody profile (IIF microscopy and ELISA); histopathological findings (subepidermal blistering, inflammatory infiltrate and eosinophilic infiltrate intensity); DIF pattern; treatment for BP; need for hospitalization; and cause and date of death, particularly in BP-N.

Neurological morbidities were assessed based on whether they preceded the onset of BP or were developed during its course, as precise dates of diagnosis and medication were difficult to ascertain based, only, on health records.

Table 1 Neurological comorbidities in patients with BP included in the study.

Neurological disease	BP-N (n, %) (n = 102)	All patients with BP (n, %) (n = 257)
Senile dementia	26 (25.5)	26 (10.1)
Alzheimer's disease	26 (25.5)	26 (10.1)
Vascular dementia	26 (25.5)	26 (10.1)
Parkinson's disease	17 (16.6)	17 (6.6)
Amyotrophic lateral sclerosis	3 (2.9)	3 (1.2)
Multiple sclerosis	2 (2)	2 (0.8)
Lewy body dementia	2 (2)	2 (0.8)

BP: bullous pemphigoid; BP-N: bullous pemphigoid patients with neurological comorbidities.

BP cases were categorized into 4 groups based on BSA involvement: generalized (> 50%), trunk and extremities (< 50%), trunk (< 50%), extremities (< 50%) and other (when not corresponding to prior criteria). Scalp and mucosal involvement were also recorded.

Due to lack of information drawn from the health records, we were unable to assess the presence of an inflammatory/non-inflammatory phenotype or estimate any disease severity score (BPDAL or IGA).

Skin biopsy with hematoxylin and eosin (H&E) stain and DIF was used in all patients included in the study. Skin lesion samples were reviewed to evaluate the presence of subepidermal bullae and inflammatory infiltrate and the intensity of the eosinophilic infiltrate.

In relation to the eosinophilic infiltrate, 6 μ m sections from skin lesion samples were stained with hematoxylin-eosin (H&E) to evaluate intensity. Representative hotspots were identified and reviewed by 2 different expert dermatopathologists and 2 dermatologists; the number of eosinophils was assessed using a 40 \times high power field (HPF) objective (scale bar: 100 μ m). We distinguished a total of 3 categories: present, very intense (++), when > 21; present, not very intense (+), when 5–20; not present or scant (–), when < 5 eosinophils/HPF.

To assess the level of the blister and differentiate BP from other subepidermal bullous diseases, type IV collagen immunohistochemical staining was used. Staining at the dermal portion of the bullae was considered to be compatible.

Anti-BP180 IgG antibodies detected were the ones directed vs the noncollagenous 16A domain (NC16A). This laboratory test was included in a commercially available ELISA kit that included the detection of IgG autoantibodies vs desmoglein 1, desmoglein 3, BP180 and type VII collagen ("MESACUP anti-Skin profile TEST"). Full-length BP180 and BP230 autoantibodies detection were not tested due to unavailability. Anti-epidermal basement membrane and anti-intercellular cement substance antibodies were detected using IIF.

Statistical analysis

Categorical variables were expressed as total number with percentages and the continuous ones as means, with standard deviation in symmetric distributions or medians and interquartile ranges in asymmetric variables.

Demographic, clinical, histopathological and laboratory characteristics were compared between BP-N and non-BP-N

groups, using the chi-square test (or Fisher's exact test when necessary) for categorical variables and the Student's *t*-test (or Mann-Whitney *U*-test/Wilcoxon *W*-test when necessary) for continuous variables. Bilateral *f*-test was used for the equal variance test. Statistical analysis was performed using Stata (version 16 StataCorp, College Station, Texas, United States).

Results

A total of 257 BP cases were included, 59.9% of whom were men. The mean age at diagnosis was 80.49 ± 10.83 years. Of these, 102 (39.7%) were diagnosed with a neurological disease at the time of BP diagnosis, with senile dementia, Alzheimer's disease and vascular dementia being the most common ones. In all cases, the neurological condition preceded the onset of BP. No patients were diagnosed with > 1 neurological illness. Neurological comorbidities of the patients included in this study are shown in Table 1.

In 60 cases, new drugs were introduced within a matter of 6 months prior to BP diagnosis including psychotropic drugs [donepezil (*n* = 1) and lacosamide (*n* = 1)], antibiotics [ciprofloxacin (*n* = 2), levofloxacin (*n* = 1), moxifloxacin (*n* = 1) and rifampicin (*n* = 1)] and dipeptidyl peptidase 4 inhibitors (DPP4i) [vildagliptin (*n* = 27), linagliptin (*n* = 17), sitagliptin (*n* = 5) and saxagliptin (*n* = 2)]. A total of 19 patients in whom the introduction of DPP4i was present and 2 cases of psychotropic drugs (donepezil and lacosamide) corresponded to the BP-N group.

There were no significant differences in the epidemiological and clinical characteristics (BSA) across the groups (Table 2).

However, immunopathological and serological differences were notable across the groups (Table 3). Despite the absence of differences in blood eosinophilia at diagnosis, the median absolute eosinophil count was higher in the BP-N group (*p* = 0.000).

Moreover, compared with the non-neurological group, the BP-N group had elevated eosinophilic inflammatory infiltration (tissular eosinophilia) which was quantified as "present, very intense" (76.5% vs 62%) (*p* = 0.012) (Table 3).

Compared with the non-neurological BP group, BP-N patients had a similar positivity rate (> 9 U/mL) of anti-BP180-NC16A IgG (*p* = 0.143), but a higher concentration of these antibodies (*p* = 0.007). Serological studies were performed in 66 patients (64.7%) of the BP-N group.

Table 2 Inter-group comparison of the epidemiological and clinical features.

	BP-N (n, %) n = 102	Non-neurological BP (n, %) n = 155	p-Value
Mean age (\pm SD) (years)	81.66 (\pm 9.06)	77 (\pm 10.88)	0.078
Sex			0.771
Female	42 (41.2)	61 (39.4)	
Male	60 (58.8)	94 (60.6)	
Clinical presentation (% affected BSA)			0.163
Generalized (>50%)	35 (34.3)	46 (29.6)	
Trunk and extremities (<50%)	51 (50.0)	71 (45.8)	
Trunk (<50%)	5 (4.9)	8 (5.2)	
Extremities (<50%)	11 (10.8)	28 (18.1)	
Other (<50%)	0	2 (1.3)	
Scalp involvement			0.563
Yes	10 (9.8)	12 (7.7)	
No	92 (90.2)	143 (92.3)	
Mucosal involvement			0.853
Yes	6 (5.9)	10 (6.5)	
No	96 (94.1)	145 (93.5)	
Pruritus	102 (100)	155 (100)	0.764
Symmetrical lesions			0.689
Yes	97 (95.1)	149 (96.1)	
No	5 (4.9)	6 (3.9)	

BP: bullous pemphigoid; BP-N: bullous pemphigoid patients with neurological comorbidities; BSA: body surface area; NS: not significant.

The highest median anti-BP180 antibodies titer was found among patients with Alzheimer's disease [84.01 U/mL, interquartile range (IQR) 87.43], followed very closely by multiple sclerosis (86.93 U/mL). Vascular dementia exhibited the lowest median antibodies titer (12.23 U/mL, IQR 61.26) (Table 4).

There were no differences in terms of recurrence/flare (p=0.181) or need for hospitalization (p=0.773). However, regarding therapy, although the number of lines of therapy needed to achieve disease control was similar (p=0.253), BP-N patients required higher doses of systemic corticosteroids (>0.5 mg/kg/day) (p=0.035) (Table 3). In terms of survival time in the global cohort (n=257), doses >0.5 mg/kg/day were not associated with poor prognosis (length of stay and/or death).

At the time of data collection, the number of deceased patients was significantly higher in the BP-N group (n=78, 76.5% vs n=77, 49.7%) (p=0.000). In BP-N cases, mean time to death from BP diagnosis was 5.37 ± 0.57 years, which is lower than that of the general cohort (6.69 ± 0.42 years). In BP-N, 5 patients died within the same year and another 5 1 year after BP diagnosis.

Discussion

Our observations suggest the strong relationship between BP patients and neurological comorbidities, particularly in relation to increased absolute eosinophil count, tissular eosinophilia, autoantibody titers and mortality, especially within the first few years after diagnosis.

Numerous studies have provided solid and convincing evidence for this association.^{10-16,18-20} Compared with the general population, patients with neurologic diseases – specifically neurodegenerative – have been estimated to have a 1.8- to 10.7-fold higher risk of developing BP.^{11,14,19}

Preceding studies have reported that 30% up to 60% of BP cases have, at least, 1 neurological disorder during the course of their dermatological disease usually already present at the moment of diagnosis of BP.¹²⁻¹⁴ Furthermore, some authors would consider this relationship only if the neurologic illness precedes the dermatological process.^{19,20}

In different retrospective case-control studies,¹²⁻¹⁴ a very significant relationship was found between BP and neurological diseases (p<0.01), with senile dementia being the most common comorbidity. Notably, patients with BP-N were older than those with non-neurological BP.^{13,14}

Following in the footsteps of previous research, we found that 39.7% of BP patients had neurological conditions at BP diagnosis. Senile dementia, Alzheimer's disease and stroke/vascular dementia were the most common comorbidities in our cohort. However, we could not find any differences in age and sex between BP-N and non-neurological BP.

Furthermore, a strong relationship with psychiatric diseases has been reported,^{19,20} and psychotropic and central nervous system drugs have been associated with the development of BP.^{4,8,9} Varpuluoma et al.⁸ found that exposure to pericazine, melperone, haloperidol, biperiden and risperidone in the prior 2 years was associated with an increased risk for BP.

Table 3 Immunological, histopathological, progression characteristics, and inter-group comparison.

	BP-N (n, %) n = 102	Non-neurological BP (n, %) n = 155	p-Value
Blood eosinophilia (>500 cells/mm³)	32 (31.4)	37 (23.9)	0.163
Absolute eosinophil count			0.000
Median [IQR] (cells/mm ³)	500 [700]	300 [575]	
Intensity of eosinophilic infiltrate (H&E)			0.012
Present, very intense (++)	78 (76.5)	96 (62)	
Present, not intense (+)	22 (21.5)	57 (36.8)	
Not present (–)	2 (2)	2 (1.2)	
Histopathological characteristics (H&E)			
Subepidermal blistering	102 (100)	154 (99.4)	0.235
Inflammatory infiltrate	100 (98.3)	152 (98.6)	0.633
Direct immunofluorescence pattern (DIF)			0.173
Linear IgG + C3	76 (74.5)	96 (61.9)	
Linear C3	20 (19.5)	40 (25.8)	
Linear IgG	2 (2)	3 (1.9)	
Linear IgG + C3 + IgM	2 (2)	9 (5.8)	
Linear C3 + IgM	1 (1)	0	
Linear C3 + IgM + IgA	1 (1)	1 (0.6)	
Fibrinogen	0	5 (3.2)	
Negative DIF	0	1 (0.6)	
Anti-BP180 antibodies detection (ELISA)			0.143
Positive (>9 U/mL)	49 (48.3)	66 (42.9)	
Negative	17 (16.7)	38 (22.4)	
Total	66 (64.7)	104 (67.1)	
Anti-BP180 antibodies concentration (ELISA)			0.007
Mean (±SD) (U/mL)	62.06 (±57.8)	40.24 (±48.9)	
Median (IQR) (U/mL)	47.44 [95.02]	16.36 [64.1]	
Prescribed treatments			0.035
Topical corticosteroids	102 (100)	155 (100)	
Systemic corticosteroids	94 (92.2)	122 (78.7)	
<0.5 mg/kg/day	77 (75.5)	101 (65.2)	
>0.5 mg/kg/day	17 (16.7)	11 (7.1)	
Tetracyclines	12 (11.8)	17 (10.9)	
Azathioprine	25 (24.5)	38 (24.5)	
Methotrexate	8 (7.8)	13 (8.4)	
Dapsone	4 (3.9)	7 (4.5)	
Rituximab	0	6 (3.9)	
Number of prescribed treatments			0.253
Mean (±SD)	1.88 (±0.81)	2.18 (±0.98)	
Median	2	2	
Number of recurrences			0.181
0	83 (81.4)	115 (74.2)	
1	15 (14.7)	30 (19.4)	
2	3 (2.9)	7 (4.5)	
3	1 (1)	2 (1.3)	
4	0	1 (0.6)	
Hospitalization (days)	38 (37.5)	55 (35.5)	0.773
Deceased at the time of data collection	78 (76.5)	77 (49.7)	0.000

BP: bullous pemphigoid; BP-N: bullous pemphigoid patients with neurological comorbidities; C3: C3 complement; DIF: direct immunofluorescence; ELISA: enzyme-linked immunosorbent assay; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M; IQR: interquartile range (p25–p75); H&E: hematoxylin–eosin; mm³: cubic millimeter; n: total number; NS: not significant.

Table 4 Rate of detection and concentration of antiBP-180 autoantibodies based on neurological comorbidities.

Neurological disease	Positive anti-BP180 antibodies (n, %)	Negative anti-BP180 antibodies (n, %)	Anti-BP180 antibody concentration Mean (\pm DS) (U/mL)	Anti-BP180 antibody concentration Median (IQR) (U/mL)
Senile dementia	10 (9.8)	3 (2.9)	54.23 (\pm 57.01)	40.96 (80.91)
Alzheimer's disease	18 (17.6)	1 (1)	96 (\pm 64.11)	84.01 (87.43)
Vascular dementia	9 (8.8)	8 (7.8)	37.79 (\pm 47.01)	12.23 (61.26)
Parkinson's disease	8 (7.8)	4 (3.9)	50.19 (\pm 49.05)	36.85 (91.71)
Amyotrophic lateral sclerosis	1 (1)	0	46.12	46.12
Multiple sclerosis	1 (1)	0	89.63	89.63
Lewy body dementia	1 (1)	1 (1)	65.56 (\pm 83.15)	65.56

Anti-BP180 antibodies positive detection was considered when >9 U/mL.

Controversially, other studies have demonstrated the null relationship that exists between these drugs and the disease and have attributed the connection to the underlying neurological/psychiatric disorder rather than drugs themselves.²¹ It has also been postulated that the coexistence of BP and neurological diseases is merely a coincidence due to these patients' advanced age.^{19–21}

Therefore, the underlying mechanism, which is either the pathophysiology of the disorder or the prescribed drug for its control, is largely unknown and still a matter of discussion.²² Appropriate and well-designed studies are needed to investigate the independent effect of neuropsychiatric drugs on the development of BP.

In 1 study on the impact of DPP4i [which are oral drugs indicated for the treatment of type 2 diabetes mellitus (T2DM)] on the development of BP, the prevalence of stroke/vascular dementia was higher in the DPP4i group vs the non-DPP4i group ($p=0.015$).²³

In our series, a total of 51 patients had been exposed to DPP4i prior to BP diagnosis; 9 of the 19 BP-N patients on DPP4i therapy had vascular dementia. Although relevant, these results should be interpreted with caution as T2DM could be a confounding factor, given its inherent cardiovascular and cerebrovascular risks.

Recent research has focused on characterizing BP-N highlighting it as a distinct subtype of BP, characterized by more intense tissue eosinophilic infiltrate, higher autoantibody levels, severe disease, worse prognosis, and higher mortality rates.^{10,11,13–16,24,25}

In a retrospective study, Baum et al.²⁵ reviewed the correlation of tissular eosinophilia with treatment response, comorbidities and course of the disease in 137 patients with BP. Neurological illnesses including Parkinson's disease, dementia, stroke, epilepsy and multiple sclerosis were present in 39 cases (28.47%), most of which (48.4%) had significant tissue eosinophilic infiltration ($p=0.011$).

This association was also observed in our cohort. We also found that the absolute eosinophil count was higher in the BP-N group vs the non-neurological BP one ($p<0.001$). Moreover, we observed relatively high anti-BP180 autoantibody titers in patients with BP-N ($p=0.007$), especially those with Alzheimer's disease.

Both anti-BP180 and anti-BP230 autoantibodies have been demonstrated in BP-N cases,^{11,15,16} given a more significant association with the latter.¹⁵ Autoantibodies

are markers of BP activity²⁶ and high antibody titers, and blood and tissue eosinophilia have been associated with inflammation,²⁶ greater disease severity^{27,28} and increased mortality, which involves the need for aggressive therapy.²⁹

The pathogenesis of neurologic illnesses, specifically in terms of neurodegeneration, is based on neuroinflammation.³⁰ Given the frequent coexistence of BP and neurological disorders, the chronological relationship and the existence of neural isoforms of BP180 and BP230, the link between BP and neurological diseases is thought to involve neuroinflammation, which could expose BP180 and BP230, thus leading to the production of autoantibodies.

These circulating autoantibodies may migrate to the skin, generate a crosslink reaction binding to cutaneous BP180 and BP230 at the dermoepidermal junction, ultimately resulting in blister formation. However, the exact mechanisms of this neurocutaneous connection remain unclear and further evidence and studies are needed to establish the appropriate and concrete connection.

Conclusions

This extensive case series, with the limitations of a retrospective study, highlights the importance of neurological comorbidities in BP patients. Our observations, consistent with existing literature, suggest that BP-N is associated with higher anti-BP180 autoantibody levels, tissular eosinophilia and increased mortality, particularly in the early years following diagnosis. These features have been associated with systemic inflammation, disease severity, and poor prognosis. Therefore, clinicians should consider neurological comorbidities when having to make a decision on the therapeutic strategies for BP patients to ensure adequate disease control.

Ethical approval

This study was reviewed and approved the ethics committee of the Hospital General Universitario Gregorio Marañón (CEIC). Approval from our ethics institutional board was obtained prior to the design and production of this paper. This study was carried out in accordance with the Declaration of Helsinki.

Data source statement

LMNB had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of data analysis.

Funding

The authors have not received any financial support or funding on this project.

Conflict of interest

Authors declare no conflict of interests for this article.

References

1. Cozzani E, Marzano AV, Caproni M, Feliciani C, Calzavara-Pinton P, Cutaneous Immunology Group of SIDeMaST. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. *G Ital Dermatol Venereol*. 2018;153:305–15, <http://dx.doi.org/10.23736/S0392-0488.18.06006-6>.
2. Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population-based cohort study. *Br J Dermatol*. 2021;184:68–77, <http://dx.doi.org/10.1111/bjd.19022>.
3. Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. *Front Med (Lausanne)*. 2018;5:220, <http://dx.doi.org/10.3389/fmed.2018.00220>.
4. Liu SD, Chen WT, Chi CC. Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. *JAMA Dermatol*. 2020;156:891–900, <http://dx.doi.org/10.1001/jamadermatol.2020.1587>.
5. Petrera MR, Tampoia M, Guida S, Abbracciavento L, Fumarulo R, Foti C. Bullous pemphigoid and neurologic diseases: toward a specific serologic profile? *Endocr Metab Immune Disord Drug Targets*. 2018;18:662–4, <http://dx.doi.org/10.2174/1871530318666180731115226>.
6. Chen J, Li L, Chen J, Zeng Y, Xu H, Song Y, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. *Gerontology*. 2011;57:211–6, <http://dx.doi.org/10.1159/000315393>.
7. Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. *Lancet Public Health*. 2020;5:e551–67, [http://dx.doi.org/10.1016/S2468-2667\(20\)30190-0](http://dx.doi.org/10.1016/S2468-2667(20)30190-0).
8. Varpuluoma O, Jokelainen J, Försti AK, et al. Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case-control study. *J Am Acad Dermatol*. 2019;81:250–3, <http://dx.doi.org/10.1016/j.jaad.2019.02.017>.
9. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. *JAMA Dermatol*. 2013;149:58–62, <http://dx.doi.org/10.1001/2013.jamadermatol.376>.
10. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2016;30:2007–15, <http://dx.doi.org/10.1111/jdv.13660>.
11. Messingham KN, Miller AD, Narayanan NS, Connell SJ, Fairley JA. Demographics and autoantibody profiles of pemphigoid patients with underlying neurologic diseases. *J Invest Dermatol*. 2019;139, <http://dx.doi.org/10.1016/j.jid.2019.01.034>, 1860–6.e1.
12. Papakonstantinou E, Limberg MM, Gehring M, Kotnik N, Kapp A, Gibbs BF, et al. Neurological disorders are associated with bullous pemphigoid. *J Eur Acad Dermatol Venereol*. 2019;33:925–9, <http://dx.doi.org/10.1111/jdv.15444>.
13. Kalinska-Bienias A, Lukowska-Smorawska K, Jagielski P, Kowalewski C, Wozniak K. Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. *Arch Dermatol Res*. 2017;309:709–19, <http://dx.doi.org/10.1007/s00403-017-1772-x>.
14. Kalińska-Bienias A, Kowalczyk E, Jagielski P, Bienias P, Kowalewski C, Woźniak K. The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: case-control study in a specialized Polish center. *Adv Clin Exp Med*. 2019;28:637–42, <http://dx.doi.org/10.17219/acem/90922>.
15. Ständer S, Hammers CM, Vorobyev A, Schmidt E, Hundt JE, Sadik CD, et al. Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-BP230 seropositivity. *J Eur Acad Dermatol Venereol*. 2021;35:2067–73, <http://dx.doi.org/10.1111/jdv.17304>.
16. Wang Y, Mao X, Wang D, Hammers CM, Payne AS, Wang Y, et al. Anti-BP180 autoantibodies are present in stroke and recognize human cutaneous BP180 and BP180-NC16A. *Front Immunol*. 2019;10:236, <http://dx.doi.org/10.3389/fimmu.2019.00236>.
17. Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). *J Eur Acad Dermatol Venereol*. 2022;36:1689–704, <http://dx.doi.org/10.1111/jdv.18220>.
18. Kridin K, Hübner F, Recke A, Linder R, Schmidt E. The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study. *J Eur Acad Dermatol Venereol*. 2021;35:2074–8, <http://dx.doi.org/10.1111/jdv.17465>.
19. Försti AK, Jokelainen J, Ansakorpi H, Seppänen A, Majamaa K, Timonen M, et al. Psychiatric and neurological disorders are associated with bullous pemphigoid – a nationwide Finnish Care Register study. *Sci Rep*. 2016;6:37125, <http://dx.doi.org/10.1038/srep37125>.
20. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. *J Invest Dermatol*. 2011;131:631–6, <http://dx.doi.org/10.1038/jid.2010.357>.
21. Kridin K, Zelber-Sagi S, Kridin M, Cohen AD. Bullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions? *J Am Acad Dermatol*. 2023;88:e137, <http://dx.doi.org/10.1016/j.jaad.2019.03.091>.
22. Varpuluoma O, Jokelainen J, Tasanen K, Huillaja L. Reply to: Comment on “Bullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions?”. *J Am Acad Dermatol*. 2023;88:e139, <http://dx.doi.org/10.1016/j.jaad.2019.04.025>.
23. Lindgren O, Varpuluoma O, Tuusa J, Ilonen J, Huillaja L, Kokkonen N, et al. Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4/CD26 in bullous pemphigoid. *Acta Derm Venereol*. 2019;99:602–9, <http://dx.doi.org/10.2340/00015555-3166>.
24. Gambichler T, Segert H, Höxtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. *J Eur Acad Dermatol Venereol*. 2015;29:1758–62, <http://dx.doi.org/10.1111/jdv.12995>.

25. Baum S, Engler Markowitz M, Lyakhovitsky A, Gershon R, Aviv H, Segal Z, et al. Skin eosinophil counts in bullous pemphigoid as a prognostic factor for disease severity and treatment response. *Acta Derm Venereol.* 2023;103, <http://dx.doi.org/10.2340/actadv.v102.2938>, adv00850.
26. Ujiie H. What's new in the pathogenesis and triggering factors of bullous pemphigoid. *J Dermatol.* 2023;50:140–9, <http://dx.doi.org/10.1111/1346-8138.16654>.
27. Gore Karaali M, Koku Aksu AE, Cin M, Leblebici C, Kara Polat A, Gurel MS. Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid. *Australas J Dermatol.* 2021;62:e236–41, <http://dx.doi.org/10.1111/ajd.13547>.
28. Park SH, Lee SH, Kim JH, Kim SC. Circulating eosinophil and neutrophil counts correlate with disease severity in bullous pemphigoid. *Ann Dermatol.* 2018;30:544–9, <http://dx.doi.org/10.5021/ad.2018.30.5.544>.
29. Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. *Br J Dermatol.* 2018;179:1141–7, <http://dx.doi.org/10.1111/bjd.16679>.
30. Julio TA, Vernal S, Massaro JD, Silva MC, Donadi EA, Moriguti JC, et al. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms. *Immunol Res.* 2018;66:567–76, <http://dx.doi.org/10.1007/s12026-018-9028-1>.